For years, scientists thought they understood the job of a protein called TRPM2. It sits on the endings of sensory nerves and detects mild, non-painful warmth. That seemed to settle the question of what it does.
Now, researchers at the University of Warwick say that picture was incomplete. In a study published September 16 in the Proceedings of the National Academy of Sciences, they found that TRPM2 also acts as a direct pain switch in nerve cells. More strikingly, when they blocked the protein in mice with arthritis, the pain disappeared even though the joints remained inflamed.
That separation between pain and inflammation is what makes the discovery especially interesting. Instead of trying to dampen the immune response, scientists may be able to target the nerve signal itself.
For people living with chronic pain, that could eventually offer another route to relief. But the research is still in mice, and several important questions remain unanswered.
The Warmth Sensor Had a Second Job
A protein filed under “harmless” has a much less pleasant side.
Warmth sensing appears to be only a small part of TRPM2’s work. It accounts for warmth sensitivity in fewer than 3.5% of the sensory neurons that carry it, leaving the protein’s role in the rest of those neurons unclear.
Dr. Xuming Zhang’s team at Warwick’s School of Life Sciences found that TRPM2 can convert immune and inflammatory signals into the electrical impulses the brain interprets as pain. Zhang describes it as a “convergent pain switch.”
Two signals can activate it: prostaglandin E2, an inflammatory chemical that rises in arthritis, and IgG immune complexes, autoantibodies bound to the body’s own proteins.
What makes the mechanism even more unusual is how those signals reach the channel. Prostaglandin E2 connects through a G protein subunit called GαoA, while the immune complexes use a receptor called FcγRI. Both bypass the cell’s usual signaling machinery. The experiments also challenge an earlier theory that another channel, TRPC3, caused pain from autoantibodies.
One Injection, Two Days of Relief
The mouse results went further than the team expected.
In one set of experiments, the researchers deleted TRPM2 specifically in sensory neurons. Chronic arthritis pain and nerve-injury pain dropped markedly, yet there was no major change in inflammation or joint damage. Pain caused by prostaglandin E2 or the immune complexes was abolished.
The team then moved from gene deletion to a drug test. A TRPM2 blocker injected into an arthritic joint completely reversed the pain, and a single dose continued to work for two days.
Zhang said to Warwick that durability was one of the clearest surprises: “What surprised us most was how completely and how long TRPM2 blockade relieved chronic arthritis pain.”
Related: Why It Gets Harder to Sleep as You Age, and What’s Really Happening Inside Your Body at Night
Pain Relief Without the Immune Trade-Off
Today’s arthritis drugs mostly work by turning something down in the immune system.
Methotrexate and NSAIDs largely target immune activity or inflammation. Yet the relief they provide can be incomplete or short-lived. Meanwhile, drugs that suppress the immune system can increase infection risk.
That trade-off matters because the need is substantial. Chronic pain, including pain associated with arthritis, affects more than one-third of U.K. adults.
TRPM2 offers a different strategy. Zhang’s team sees it as a direct pain pathway that operates alongside inflammation rather than simply being a consequence of it. In theory, a drug could block the nerve signal while leaving the immune system’s broader function intact.
That possibility could make chronic pain easier to treat than it is with current options.
Where the Picture Gets Complicated
A few details keep this from being as tidy as the headline sounds.
The full paper adds an important wrinkle for nerve-injury pain. TRPM2 appears to matter during roughly the first 14 days after an injury. By day 28, however, the pain returned in the knockout mice, and the blocker no longer reversed it.
That change lines up with what happened to the signals feeding the pathway. Prostaglandin E2 and IgG levels in the relevant sensory nerve tissue dropped toward baseline, suggesting that TRPM2’s role may fade as those signals fade.
That still leaves several major questions. Would blocking TRPM2 produce the same degree and duration of relief in people? What would happen with long-term blockade, considering that the channel also has roles in immune cells and oxidative stress? And because the mice received the treatment by injection directly into the joint, developing a pill would present a separate challenge. How often people would need a treatment is unknown.
The Check-Engine-Light Objection
Image Credit: chormail/123RF
Not everyone hears “switch off pain” as good news.
It is a fair point, particularly for a condition in which inflammation can damage joints over time. The researchers, however, see the approach mainly as an option when controlling inflammation does not provide enough relief or carries unacceptable risks.
Still, the mouse experiments were short-term. They cannot show whether blocking TRPM2 for months would affect how arthritis progresses, how much joint damage occurs, or how tissue repairs itself. Those are important questions for future studies.
Drug Developers Are Already Circling
Biohaven has filed patents on TRPM2 blockers for pain, while it already has a blocker targeting the related channel TRPM3 in Phase 2 testing for migraine and pain.
A March 2026 IUPHAR review had also cataloged several approaches to inhibiting TRPM2, including ADPR analogs, small molecules and peptides. At the same time, other channels in the same family, including TRPV1, have produced mixed results as pain targets because of side effects such as raised body temperature and sensory loss.
That activity does not mean a TRPM2 treatment is close. The Warwick paper describes no human trials, regulatory filings, or commercialization plans.
For now, Zhang’s team is interested in one particularly useful possibility: that different groups of TRPM2-carrying neurons may control warmth and pain. The researchers hope to test that next. If the distinction holds, a future drug can block the pain pathway without interfering with the ability to sense warmth.
And that may be the more interesting question than whether scientists can switch pain off: can they do it without switching off something the body still needs?
More Articles You Might Be Interested in:
The post Scientists Uncover a “Pain Switch” That Could Help Ease Arthritis Pain appeared first on FODMAP Everyday.